Cargando…
Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
BACKGROUND: Reduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β(2)-agonist olodaterol increases exercise capacity. This study assessed the effe...
Autores principales: | Valipour, Arschang, Tamm, Michael, Kociánová, Jana, Bayer, Valentina, Sanzharovskaya, Maria, Medvedchikov, Alexey, Haaksma-Herczegh, Monika, Mucsi, János, Fridlender, Zvi, Toma, Claudia, Belevskiy, Andrey, Matula, Bohumil, Šorli, Jurij |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6793952/ https://www.ncbi.nlm.nih.gov/pubmed/31632003 http://dx.doi.org/10.2147/COPD.S204388 |
Ejemplares similares
-
Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study
por: Valipour, Arschang, et al.
Publicado: (2021) -
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018) -
Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019) -
Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study
por: Minakata, Yoshiaki, et al.
Publicado: (2019) -
Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)